Diabetes, weight loss drug companies growth far from over, says ClearBridge analyst

ClearBridge research analyst Marshall Gordon sits down with InvestmentNews anchor Gregg Greenberg to discuss the rise of new diabetes and weight-loss drugs, as well as the best ways to invest in this burgeoning sector.
  • Aug 30, 2023
More: IN THE NASDAQ
Commodity allocation remains crucial as inflation still untamed

Commodity allocation remains crucial as inflation still untamed

How parents can balance both retirement and college saving

How parents can balance both retirement and college saving

MSCI strategist breaks down the biggest trends in wealth management 

MSCI strategist breaks down the biggest trends in wealth management